Articles On Actinogen Medical (ASX:ACW)

ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios   Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg...

ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios   The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Actinogen Medical (ACW) receives approval from the USA FDA to proceed with its six-month, phase 2b, placebo-controlled clinical trial of Xanamem Under the planned trial, Actinogen will enrol 330 patients with mild Alzheimer’s Disease and...

Actinogen Medical is a biotech with a potentially "gazillion" dollar opportunity in its Alzheimer's drug. By Tim Boreham ASX code: ACW Market cap: $215.7 million Share price: 12 cents Shares on issue: 1,797,393,817 Chief executive officer:...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeWebinar Recap – ACW, EEG & KNB Catch up on the full webinar presentations from Actinogen Medical (ASX: ACW), Empire Energy (ASX: EEG) & Koonenberry Gold (ASX: KNB) Webinar Recap – ACW, EEG & KNBCompany News

ShareCafeActinogen Medical (ASX:ACW) – Webinar Presentation Dr. Steven Gourlay – Managing Director & CEO – Actinogen Medical is a biotechnology company developing an innovative treatment for cognitive impairment associated with neurolo...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ASX 200 ends 1.4% lower Small caps slide 0.4% Strike strikes and I don’t know why    The ASX 200 and the Emerging Companies (XEC) index fell 1.4% and 0.4% respectively on Monday. US stocks were no help at all after collapsing sharply on F...

ASX 200 abandoned play after decent start Small cap index gives back 1.3% Dundas shares jump on ultramafic magic   Local markets disappointed me today. So rather than start on an ill note, let’s take a quick spin around the Asia-Pacific...

Clinical Dementia Rating Scale – Sum of Boxes effect of 0.6 to 0.8 points observed in patients with elevated pTau biomarker with once daily, 10 mg, oral therapy SYDNEY, Oct. 10, 2022 /PRNewswire/ – Actinogen Medical Limited (ASX: ACW) today...

Actinogen Medical (ACW) sees new “positive” data from its phase 2A Alzheimer Disease (AD) biomarker studyThe study tested the company’s drug, Xanamem, on 72 patients across the US, UK and Australia with previously identified mild ADResults...

ASX slides early and long on Monday Small cap index crashes -2.3% Besra Gold (ASX:BEZ) just tripled its own sense of self   We’re all in the same boat on Monday, floating aimlessly about the big blue of the Pacific amidst inflation and it...

The share market started the week with a sharp loss as investors booked profits from last week’s rally ahead of US inflation data and a new US earnings season. The S&P/ASX 200 slumped 95 points or 1.4 per cent to a second-straight de...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and dropped deep into the red. At the time of writing, the benchmark index is down 1.5% to 6,662.6 points. Four ASX shares that are not letting that h...

The S&P/ASX 200 Index (ASX: XJO) is down 1.69% today, but one ASX biotech share is bucking the trend. The Actinogen Medical Ltd (ASX: ACW) share price soared 56% in early trade before pulling back. The company’s share price is up 30%...

ShareCafeRough start to the week, all sectors in the red: ASX down 1.4 per cent at noon by Lauren Hayes   It was always going to be a dismal start to the trading week following Wall Street tumbling on Friday, after a stronger-than-expected...

ShareCafeStocks of the Hour: HLX, ACW, GAL                    Helix Resources (ASX:HLX) provided an update this morning on the ongoing copper exploration drilling at its Canbelego Joint Venture Project located in the Cobar region of N...

10 Oct 2022 - A snapshot of the stocks on the move featuring Helix Resources (ASX:HLX), Actinogen Medical (ASX:ACW) and Galileo Mining (ASX:GAL).

Australian shares fell for a second day as US equity futures retreated ahead of inflation data and the start of a new earnings season later this week. The S&P/ASX 200 declined 105 points or 1.55 per cent to 6658 by mid-session. The i...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Benchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s worn out its welcome in QLD A solid arvo by little league miners was a well-timed boost It’s been a somewhat indecisive day for Aussie mark...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Actinogen Medical (ASX:ACW) has provided further information on the timing and design of its upcoming biomarker study in patients with mild Alzheimer’s disease.

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Actinogen Medical (ACW) finalises the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD) The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and dep...

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Highlights The ASX Small Ordinaries index surged 1.59% to 2,987 by 12:30 PM AEST today. OZM, SBW and ACW are three ASX penny stocks racking up high gains today. Investors must do proper due diligence before investing in penny stocks....

Actinogen (ACW) announced it will prioritises its phase two trials in Alzheimer’s disease and depression Following results in the company’s recent double-blind XanaMIA Part A trial, Actinogen conducted a reassessment of its priorities and...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Actinogen Medical (ACW) confirms positive topline results from its XanaMIA Part A trial, meeting primary safety, pharmacodynamic and efficacy endpoints Results from the trial confirm Xanamem’s ability to enhance cognition and are consisten...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX will head into the Anzac day long weekend on a slightly sour note following a Friday selloff. For the microcap Emerging Companies index, it was a ~1.5% fall on the day — but that didn’t stop another triple-digit percentage return, t...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX 200 Health Index (XHJ) is down 2%, while the benchmark ASX 200 is also falling by 0.75%. The path is now open for pharma distributor Australian Pharmaceutical Industries (ASX: API) to be acquired by Wesfarmer...

Actinogen Medical (ACW) completes final participant visits for the XanaMIA Part A trial which the company says will provide analysis of the effects of its Xanamem technology Xanamem is designed as an oral therapeutic for Alzheimers Disease...

Actinogen Medical (ACW) appoints a trial manager for its XanaFX phase-two trial in adolescent boys and young adults with Fragile X Syndrome (FXS) Clinical research organisation Worldwide Clinical Trials will manage the recruitment of parti...

Motion analysis device maker dorsaVi (ASX:DVL) has been awarded the internationally recognised ISO 27001 certification, verifying the data security standards for the company . The ISO 27001 standard specifies advanced information security a...

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...